Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer disease - The European Pharmacogenetic Opioid Study (EPOS)

Torill Fladvad, Peter Fayers, Frank Skorpen, Stein Kaasa, Pål Klepstad

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective This study examined whether the choice of pain-related outcome to represent opioid efficacy influenced findings in a genetic association study. Data from the European Pharmacogenetic Opioid Study, which used opioid dose as the outcome, were analysed in respect of six alternative outcomes: average pain intensity, pain right now, worst pain intensity, pain at its least, pain relief and pain interference.

Design Cancer pain patients using an opioid for moderate or severe pain were included. The pain outcomes were obtained using the Brief Pain Inventory. Genetic variation was analysed for 112 single nucleotide polymorphisms (SNPs) in 25 candidate genes relevant for opioid efficacy. The patients were randomly divided into a development and a validation sample and linear regression was used to compare the equality of means in the six outcomes. The influence of non-genetic factors was controlled for, the regression analyses were stratified by country, and the results were corrected for multiple testing.

Results 2201 cancer pain patients were included. Their mean age was 62.4 years and mean average pain was 3.5. None of the examined SNPs exceeded p values corrected for multiple testing for any of the outcomes.

Conclusions None of the outcomes were associated with variation in the selected SNPs, as previously shown for opioid dose. Thus, we observed that findings related to associations between genetic variability and opioid efficacy were consistent for several alternative outcomes.
Original languageEnglish
Pages (from-to)351-355
Number of pages5
JournalBMJ Supportive & Palliative Care
Volume2
Issue number4
Early online date27 Sep 2012
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Opioid Analgesics
Pain
Neoplasms
Single Nucleotide Polymorphism
Pharmacogenomic Testing
Genetic Association Studies
Linear Models
Regression Analysis
Equipment and Supplies

Cite this

@article{717a6b74ce8541ef8ea3e80884bce75b,
title = "Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer disease - The European Pharmacogenetic Opioid Study (EPOS)",
abstract = "Objective This study examined whether the choice of pain-related outcome to represent opioid efficacy influenced findings in a genetic association study. Data from the European Pharmacogenetic Opioid Study, which used opioid dose as the outcome, were analysed in respect of six alternative outcomes: average pain intensity, pain right now, worst pain intensity, pain at its least, pain relief and pain interference.Design Cancer pain patients using an opioid for moderate or severe pain were included. The pain outcomes were obtained using the Brief Pain Inventory. Genetic variation was analysed for 112 single nucleotide polymorphisms (SNPs) in 25 candidate genes relevant for opioid efficacy. The patients were randomly divided into a development and a validation sample and linear regression was used to compare the equality of means in the six outcomes. The influence of non-genetic factors was controlled for, the regression analyses were stratified by country, and the results were corrected for multiple testing.Results 2201 cancer pain patients were included. Their mean age was 62.4 years and mean average pain was 3.5. None of the examined SNPs exceeded p values corrected for multiple testing for any of the outcomes.Conclusions None of the outcomes were associated with variation in the selected SNPs, as previously shown for opioid dose. Thus, we observed that findings related to associations between genetic variability and opioid efficacy were consistent for several alternative outcomes.",
author = "Torill Fladvad and Peter Fayers and Frank Skorpen and Stein Kaasa and P{\aa}l Klepstad",
year = "2012",
month = "12",
doi = "10.1136/bmjspcare-2012-000212",
language = "English",
volume = "2",
pages = "351--355",
journal = "BMJ Supportive & Palliative Care",
issn = "2045-435X",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer disease - The European Pharmacogenetic Opioid Study (EPOS)

AU - Fladvad, Torill

AU - Fayers, Peter

AU - Skorpen, Frank

AU - Kaasa, Stein

AU - Klepstad, Pål

PY - 2012/12

Y1 - 2012/12

N2 - Objective This study examined whether the choice of pain-related outcome to represent opioid efficacy influenced findings in a genetic association study. Data from the European Pharmacogenetic Opioid Study, which used opioid dose as the outcome, were analysed in respect of six alternative outcomes: average pain intensity, pain right now, worst pain intensity, pain at its least, pain relief and pain interference.Design Cancer pain patients using an opioid for moderate or severe pain were included. The pain outcomes were obtained using the Brief Pain Inventory. Genetic variation was analysed for 112 single nucleotide polymorphisms (SNPs) in 25 candidate genes relevant for opioid efficacy. The patients were randomly divided into a development and a validation sample and linear regression was used to compare the equality of means in the six outcomes. The influence of non-genetic factors was controlled for, the regression analyses were stratified by country, and the results were corrected for multiple testing.Results 2201 cancer pain patients were included. Their mean age was 62.4 years and mean average pain was 3.5. None of the examined SNPs exceeded p values corrected for multiple testing for any of the outcomes.Conclusions None of the outcomes were associated with variation in the selected SNPs, as previously shown for opioid dose. Thus, we observed that findings related to associations between genetic variability and opioid efficacy were consistent for several alternative outcomes.

AB - Objective This study examined whether the choice of pain-related outcome to represent opioid efficacy influenced findings in a genetic association study. Data from the European Pharmacogenetic Opioid Study, which used opioid dose as the outcome, were analysed in respect of six alternative outcomes: average pain intensity, pain right now, worst pain intensity, pain at its least, pain relief and pain interference.Design Cancer pain patients using an opioid for moderate or severe pain were included. The pain outcomes were obtained using the Brief Pain Inventory. Genetic variation was analysed for 112 single nucleotide polymorphisms (SNPs) in 25 candidate genes relevant for opioid efficacy. The patients were randomly divided into a development and a validation sample and linear regression was used to compare the equality of means in the six outcomes. The influence of non-genetic factors was controlled for, the regression analyses were stratified by country, and the results were corrected for multiple testing.Results 2201 cancer pain patients were included. Their mean age was 62.4 years and mean average pain was 3.5. None of the examined SNPs exceeded p values corrected for multiple testing for any of the outcomes.Conclusions None of the outcomes were associated with variation in the selected SNPs, as previously shown for opioid dose. Thus, we observed that findings related to associations between genetic variability and opioid efficacy were consistent for several alternative outcomes.

U2 - 10.1136/bmjspcare-2012-000212

DO - 10.1136/bmjspcare-2012-000212

M3 - Article

VL - 2

SP - 351

EP - 355

JO - BMJ Supportive & Palliative Care

JF - BMJ Supportive & Palliative Care

SN - 2045-435X

IS - 4

ER -